Theralink Technologies, Inc. (OTCPK: THER)
Health Care · Biotechnology · US
$—
— today · — 1Y
Theralink Technologies, Inc. (OTCPK: THER) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.15K and employs 16 people.
trading between 0.00 and 0.00.
Tweenvest scores Theralink Technologies, Inc. across four factors: quality 7/100, value 47/100. Its strongest factor is value.
THER price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.15K
- Revenue (TTM)
- $635.45K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 60.01
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 6.15B
- Employees
- 16
- Next earnings
- —
About Theralink Technologies, Inc.
Theralink Technologies, Inc., headquartered in Golden, Colorado, is a commercial-stage enterprise specializing in precision medicine and the generation of crucial molecular data. The company is dedicated to advancing and bringing to market innovative cancer immunotherapy products. Utilizing its proprietary platform, which focuses on phosphoprotein and protein biomarkers, alongside its sophisticated laboratory-developed test (LDT) technology, Theralink addresses diverse aspects of oncology and pharmaceutical research. Through their specialized Theralink Reverse Phase Protein Array assays, they provide highly accurate oncology data. This information enables the biopharmaceutical industry and clinical oncologists to more precisely predict which patients will respond to, or be resistant to, both FDA-approved and investigational drug treatments. Ultimately, Theralink's diagnostic assays deliver vital, actionable insights that benefit physicians, patients, and biopharmaceutical companies operating within the field of cancer care. The company adopted its current name, Theralink Technologies, Inc., in September 2020, having previously operated as OncBioMune Pharmaceuticals, Inc.
- ISIN
- US88339Q1094
- Listed since
- Apr 1, 2010
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.